肽疫苗接种联合溶瘤病毒MG1-E6E7用于HPV相关癌症的临床前开发
本研究在 mice 模型中评估了针对HPV16和HPV18抗原的合成长肽(SLP)疫苗联合定制溶瘤Maraba病毒MG1-E6E7的效果。SLP可诱导特异性CD8+免疫应答,经MG1-E6E7加强后应答幅度显著增加,并产生多功能CD8+ T细胞,使接种小鼠获得对TC1细胞攻击的完全无菌免疫。在携带大HPV阳性肿瘤的小鼠中,联合方案使60%小鼠肿瘤清除,且这些小鼠对长期 aggressive 再攻击完全保护。
要点
- SLP疫苗联合MG1-E6E7加强可显著增加HPV特异性CD8+ T细胞应答幅度。
- 联合免疫诱导多功能CD8+ T细胞,并使小鼠获得对TC1攻击的完全无菌免疫。
- 在携带大HPV阳性肿瘤的小鼠中,联合方案使60%小鼠肿瘤清除并对再攻击完全保护。
核心结论
- 常规SLP疫苗联合多功能溶瘤病毒MG1-E6E7是应对晚期HPV阳性肿瘤的有前景方法。
研究设计与样本
- 临床前研究:使用HPV阳性TC1细胞和小鼠模型,评估溶瘤Maraba病毒MG1-E6E7及表位映射指导设计的针对HPV16和HPV18抗原的合成长肽(SLP)疫苗。
主要发现
- 用MG1-E6E7接种小鼠的表位映射使针对HPV16和HPV18抗原的SLP疫苗合理设计成为可能。
- SLP可诱导特异性CD8+免疫应答,经MG1-E6E7加强后应答幅度显著增加。
- 合理设计的疫苗接种诱导多功能CD8+ T细胞,并使小鼠对TC1细胞攻击获得完全无菌免疫。
- 在携带大HPV阳性肿瘤的小鼠中,SLP联合MG1-E6E7使60%小鼠肿瘤清除,这些小鼠对TC1肿瘤模型长期 aggressive 再攻击完全保护。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Human papilloma virus (HPV)-associated cancer is a significant global health burden and despite the presence of viral transforming antigens within neoplastic cells, therapeutic vaccinations are ineffective for advanced disease. HPV positive TC1 cells are susceptible to viral oncolysis by MG1-E6E7, a custom designed oncolytic Maraba virus. Epitope mapping of mice vaccinated with MG1-E6E7 enabled the rational design of synthetic long peptide (SLP) vaccines against HPV16 and HPV18 antigens. SLPs were able to induce specific CD8+ immune responses and the magnitude of these responses significantly increased when boosted by MG1-E6E7. Logically designed vaccination induced multi-functional CD8+ T cells and provided complete sterilising immunity of mice challenged with TC1 cells. In mice bearing large HPV-positive tumours, SLP vaccination combined with MG1-E6E7 was able to clear tumours in 60% of mice and these mice were completely protected against a long term aggressive re-challenge with the TC1 tumour model. Combining conventional SLPs with the multi-functional oncolytic MG1-E6E7 represents a promising approach against advanced HPV positive neoplasia.
引用
- Atherton MJ, Stephenson KB, Nikota JK, et al. Preclinical development of peptide vaccination combined with oncolytic MG1-E6E7 for HPV-associated cancer. Vaccine. 2018. PMID: 29544689. doi:10.1016/j.vaccine.2018.02.070
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。